Results Reinforce Merck/Kelun’s Sac-TMT As Major TROP2 Player
The companies announced Phase III data for the TROP2-directed ADC in endometrial cancer, showing the drug as a potentially strong competitor in a space that Trodelvy and Datroway dominate.
Scrip - May 18, 2026

India’s Medtech Sector Eyes $80bn Opportunity As Domestic Manufacturing Share Doubles In 3 Years
India's medical device sector has hit a genuine turning point – domestic manufacturing share has doubled, capital is flooding in, and a clutch of homegrown innovations are reaching global markets. A new report sets out exactly what is at stake and what could still go wrong.
Medtech Insight - May 18, 2026

Boston Scientific Bets $1.5bn On MiRus, Secures Option To Acquire TAVR System
The medtech giant re-enters the TAVR arena, after two major platform failures, with a 34% stake in MiRus and an exclusive option to acquire its nickel-free SIEGEL valve.
Medtech Insight - May 18, 2026

Brazil Urged To Tighten Dietary Supplement Rules
A Brazilian Chamber of Deputies working group has declared the country's food supplement regulation chaotic and called for a sweeping overhaul, as ANVISA data show supplements account for nearly two-thirds of all investigation proceedings.
HBW Insight - May 18, 2026

Amgen’s At-Risk Eylea Biosimilar Paved The Path For Biocon’s US Launch, Says CEO
Profitable growth over market share grabs, a capacity-doubled Malaysia facility and a succession plan in the making: Biocon is quietly reshaping itself for the long haul.
Generics Bulletin - May 18, 2026

Pipeline Watch: Eleven Approvals And One Phase III Readout
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - May 18, 2026

Dr Reddy’s Follows Apotex With Second Semaglutide In Canada
A second Ozempic generic has hit the Canadian market, with Dr Reddy’s following hot on the heels of Apotex with its own semaglutide offering.
Generics Bulletin - May 18, 2026

Kashiv’s “30 by 30?: A Rehashed Pipeline And Therapy-Agnostic Bet
From doubling its pipeline and what the landmark deal with Amneal means to using AI-based technology for generating high-titer clones, Kashiv BioSciences’ CEO talks to Scrip about the company’s strategy as regulatory streamlining rewrites the economics of the biosimilars sector.
Scrip - May 18, 2026

Henlius Takes Cetuximab Biosimilar Development Outside Of China
Henlius has secured US FDA clearance for an IND for its proposed biosimilar to Erbitux (cetuximab), advancing a contender in a field where scientific complexity has kept US and European markets without an approved biosimilar.
Generics Bulletin - May 18, 2026

Podcast: Europe’s Evolving Role in Global Clinical Trials
As global clinical development strategies evolve, Europe is emerging as a critical hub for scientific innovation, operational agility, and patient recruitment — reshaping its role in the future of clinical trials.
Scrip - May 18, 2026

EU Biotech Act’s SPC Extension Sparks Access And Cost Concerns
A proposed 12-month SPC extension for qualifying biotech medicines under the European Biotech Act has drawn sharp criticism from biosimilars firms, payers and patients, who warn it risks delaying competition by a year while doing little to drive European manufacturing investment.
Generics Bulletin - May 18, 2026

Bio-Thera And Accord Take Lead With First US Golimumab Nod
Bio-Thera Solutions and Accord Biopharma have together broken new ground in the US after receiving the first FDA approvals for golimumab biosimilars in the form of their partnered Immgolis and Immgolis Intri rivals to Simponi and Simponi Aria.
Generics Bulletin - May 18, 2026

Regeneron’s LAG-3 Inhibitor Fianlimab Flunks A Key Pipeline Test
The failed readout cements the lead for Bristol Myers Squibb’s blockbuster Opdualag in first-line melanoma and pulls a key 2026 catalyst out of Regeneron’s pipeline.
Scrip - May 18, 2026

BIA’s 2035 Vision For UK Health Data Goes Beyond Subscription Models
With over 200 large-scale patient datasets already competing globally, the BIA argues a subscription-fee mindset would lock out UK SMEs and hand the upside to better-funded foreign rivals.
Medtech Insight - May 18, 2026

Deals In Depth: April 2026
Six $1bn+ alliances were penned in April, and three exceeded $2bn. In the top alliance by deal value, Profluent entered a potential $2.25bn multi-program collaboration with Eli Lilly to develop and commercialize custom site-specific recombinases to address diseases with severe unmet needs.
In Vivo - May 18, 2026

The Alkermes Handover: Ambition, Jazz Settlement And Phase III Still To Come
Outgoing CEO Richard Pops built Alkermes. Now he is handing it over at precisely the moment his biggest wager on sleep medicine is entering its most consequential phase.
In Vivo - May 18, 2026

Kissei Urges Tavneos Caution In Japan After 20 Deaths
Reports of 20 deaths, including cases of vanishing bile duct syndrome, in patients in Japan receiving Tavneos make local headlines and prompt new precautionary measures by local licensee Kissei.
Scrip - May 18, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: GSK bolsters downstream obesity strategy; Novo winning early obesity pill market; Roche’s support for Switzerland under strain; Hengrui and BMS strike huge R&D alliance; PCSK9 drug Lerochol launched in US at lower direct cost.
Scrip - May 18, 2026

Las Vegas Supplement Firm’s Tall Gamble Doesn’t Measure Up To FTC Claim, Testimonial Standards
FTC says in administrative complaint that in addition to lacking competent and reliable evidence to support height growth claims for its products, Vanilla Chip used fraudulent social media ratings, posted by its employees or by consumers who received free products.
HBW Insight - May 18, 2026